Jubilant Organosys Of India Seeks CRO-Related Acquisitions In U.S., Europe (India)
This article was originally published in PharmAsia News
Executive Summary
India's Jubilant Organosys has set aside $100 million to acquire companies in the clinical research area in the United States and Europe. Specifically, Jubilant wants companies engaging in contract research and manufacturing services, drug discovery and clinical research. The company seeks to position itself as a source for outsourcing partnerships with major global drug makers and as a service provider, according to the firm's finance director. Jubilant already has contract research-organization subsidiaries in the United States and India. (Click here for more
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.